Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$995K | -$6.99M | -$8.24M | -$10.9M | -$19.3M | -$10.9M | -$6.89M | -$8.28M | -$7.80M |
| Net income | -$1.14M | -$11.6M | -$8.59M | -$10.9M | -$19.4M | -$12.7M | -$5.12M | -$13.2M | -$7.98M |
| EPS (diluted) | -$0.35 | -$2.44 | -$0.87 | -$0.87 | -$1.04 | -$12.71 | -$3.60 | -$68.01 | -$11.93 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$495K | -$2.50M | -$6.34M | -$7.63M | -$11.9M | -$11.2M | -$6.81M | -$6.92M | -$6.49M |
| Capital expenditures | — | — | — | — | $64.6K | — | — | — | — |
| Free cash flow | — | — | — | — | -$12.0M | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | $1.66K | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.2K | $3.87M | $6.78M | $4.40M | $6.06M | $4.00M | $2.83M | $3.75M | $5.88M |
| Total assets | $34.5K | $4.70M | $7.68M | $5.49M | $7.47M | $5.73M | $4.74M | $5.04M | $6.67M |
| Total liabilities | — | — | — | $1.51M | $3.97M | $2.46M | $653K | $976K | $1.40M |
| Shareholders' equity | -$998K | $4.44M | $7.14M | $3.99M | $3.51M | $3.28M | $4.08M | $4.07M | $5.28M |
| Retained earnings | -$404K | -$12.0M | -$20.6M | -$31.5M | -$50.9M | -$63.7M | -$68.8M | -$82.0M | -$90.0M |
| Shares (wtd avg diluted) | 174K | 243K | 10.4M | 14.4M | 18.6M | 1.00M | 1.42M | 194K | 669K |
Every figure is extracted from ADIAL PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.